CN114828876A - Bcl11b过表达以增强人胸腺生成和t细胞功能 - Google Patents

Bcl11b过表达以增强人胸腺生成和t细胞功能 Download PDF

Info

Publication number
CN114828876A
CN114828876A CN202080060106.4A CN202080060106A CN114828876A CN 114828876 A CN114828876 A CN 114828876A CN 202080060106 A CN202080060106 A CN 202080060106A CN 114828876 A CN114828876 A CN 114828876A
Authority
CN
China
Prior art keywords
cells
cell
bcl11b
mature
pluripotent stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080060106.4A
Other languages
English (en)
Chinese (zh)
Inventor
钦腾·帕雷克
盖伊·克鲁克斯
克里斯多夫·西特
阿梅莉·蒙特尔-哈根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Los Angeles
University of California San Diego UCSD
Original Assignee
Childrens Hospital Los Angeles
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Los Angeles, University of California San Diego UCSD filed Critical Childrens Hospital Los Angeles
Publication of CN114828876A publication Critical patent/CN114828876A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080060106.4A 2019-06-24 2020-06-24 Bcl11b过表达以增强人胸腺生成和t细胞功能 Pending CN114828876A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962865835P 2019-06-24 2019-06-24
US62/865,835 2019-06-24
PCT/US2020/039414 WO2020264019A1 (en) 2019-06-24 2020-06-24 Bcl11b overexpression to enhance human thymopoiesis and t cell function

Publications (1)

Publication Number Publication Date
CN114828876A true CN114828876A (zh) 2022-07-29

Family

ID=71842851

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080060106.4A Pending CN114828876A (zh) 2019-06-24 2020-06-24 Bcl11b过表达以增强人胸腺生成和t细胞功能

Country Status (8)

Country Link
US (1) US20220347222A1 (https=)
EP (1) EP3986427A1 (https=)
JP (1) JP2022539032A (https=)
KR (1) KR20220042353A (https=)
CN (1) CN114828876A (https=)
AU (1) AU2020301413A1 (https=)
CA (1) CA3144640A1 (https=)
WO (1) WO2020264019A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112574952A (zh) * 2019-09-30 2021-03-30 英基生物医药(香港)有限公司 一种工程化人体免疫细胞、其制备方法及应用
CN118374444A (zh) * 2024-05-24 2024-07-23 中国人民解放军军事科学院军事医学研究院 一种利用骨髓类器官体外生产人血细胞的方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
FR3130843A1 (fr) * 2021-12-21 2023-06-23 Universite Claude Bernard Lyon 1 Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt
WO2025038494A1 (en) * 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
WO2025097004A1 (en) * 2023-11-02 2025-05-08 Regents Of The University Of Minnesota Modulation of hematopoietic cells using bcl11b

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108463548A (zh) * 2015-10-30 2018-08-28 加利福尼亚大学董事会 由干细胞产生t细胞的方法及使用所述t细胞的免疫治疗方法
CN109312307A (zh) * 2016-04-08 2019-02-05 多伦多大学管理委员会 用于从干细胞和/或祖细胞生成祖t细胞的方法及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735800C (en) * 2008-09-03 2018-05-01 Angioblast Systems, Inc. Expansion of haemopoietic precursors
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012096974A1 (en) * 2011-01-10 2012-07-19 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of allogeneic hematopoietic stem cell transplantation
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
AU2014248119B2 (en) * 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
IL268641B2 (en) * 2017-02-13 2024-10-01 Assist Publique Hopitaux Paris Aphp Method for generating t cells progenitors
CA3083779A1 (en) * 2017-12-22 2019-06-27 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108463548A (zh) * 2015-10-30 2018-08-28 加利福尼亚大学董事会 由干细胞产生t细胞的方法及使用所述t细胞的免疫治疗方法
CN109312307A (zh) * 2016-04-08 2019-02-05 多伦多大学管理委员会 用于从干细胞和/或祖细胞生成祖t细胞的方法及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PERMATASARI HAPPY KURNIA ET AL: "BCL11B is frequently downregulated in HTLV-1-infected T-cells through Tax-mediated proteasomal degradation", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 490, no. 3, 29 June 2017 (2017-06-29), pages 1092, XP085135644, DOI: 10.1016/j.bbrc.2017.06.172 *
SI CHEN ET AL: "The role ofin regulating the proliferation of human naive T cells", HUMAN IMMUNOLOGY, vol. 73, no. 5, 27 February 2012 (2012-02-27), XP028417847, DOI: 10.1016/j.humimm.2012.02.018 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112574952A (zh) * 2019-09-30 2021-03-30 英基生物医药(香港)有限公司 一种工程化人体免疫细胞、其制备方法及应用
CN112574952B (zh) * 2019-09-30 2025-04-15 英基生物医药(香港)有限公司 一种工程化人体免疫细胞、其制备方法及应用
CN118374444A (zh) * 2024-05-24 2024-07-23 中国人民解放军军事科学院军事医学研究院 一种利用骨髓类器官体外生产人血细胞的方法

Also Published As

Publication number Publication date
EP3986427A1 (en) 2022-04-27
CA3144640A1 (en) 2020-12-30
KR20220042353A (ko) 2022-04-05
AU2020301413A1 (en) 2022-02-10
US20220347222A1 (en) 2022-11-03
WO2020264019A1 (en) 2020-12-30
JP2022539032A (ja) 2022-09-07

Similar Documents

Publication Publication Date Title
Tipanee et al. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy
CN114828876A (zh) Bcl11b过表达以增强人胸腺生成和t细胞功能
Wang et al. Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity
US12371471B2 (en) Immune cells defective for SUV39H1
Neidemire-Colley et al. CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model
EP4297759A1 (en) In vivo crispr screening system for discovering therapeutic targets in cd8 t cells
US20220017715A1 (en) Compositions and Methods for Efficacy Enhancement of T-Cell Based Immunotherapy
US20180066253A1 (en) Methods and compositions for modifying endothelial cells
US20250270546A1 (en) Guide rnas and uses thereof
US20240325537A1 (en) Cellular therapies for cancer by inhibition of monocarboxylate transporter 11
HK40052923A (en) Immune cells defective for suv39h1
WO2024062138A1 (en) Immune cells comprising a modified suv39h1 gene
Pais Ferreira Developmental origin of central memory CD8+ T cells
Canner Investigation of endogenous and adoptively transferred T cell function in a genetic mouse model of lung adenocarcinoma
HK40103142A (zh) 用於发现cd8 t细胞中治疗靶标的体内crispr筛选系统
HK40006610A (en) Immune cells defective for suv39h1
HK40006610B (en) Immune cells defective for suv39h1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220729

WD01 Invention patent application deemed withdrawn after publication